SRC and neoplasm: Both the FOXM1 inhibitor NB-55 and the SFKi eCF506 also significantly impaired the growth of a second PDX model established from a luminal B–like tumor (58) (Figure 10D), suppressed the expression of FOXM1 and its targets, including SRC, and significantly reduced lung metastasis in this model (Figure 10, D and E, and Supplemental Figure 11, C and D).